These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23104454)

  • 21. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE; Darwish WM; Davies MG; Waldman DL
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No Increased Mortality After TIPS Compared with Serial Large Volume Paracenteses in Patients with Higher Model for End-Stage Liver Disease Score and Refractory Ascites.
    Ronald J; Rao R; Choi SS; Kappus M; Martin JG; Sag AA; Pabon-Ramos WM; Suhocki PV; Smith TP; Kim CY
    Cardiovasc Intervent Radiol; 2019 May; 42(5):720-728. PubMed ID: 30603968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation.
    Gotthardt D; Weiss KH; Baumgärtner M; Zahn A; Stremmel W; Schmidt J; Bruckner T; Sauer P
    BMC Gastroenterol; 2009 Sep; 9():72. PubMed ID: 19778459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Importance of Combined Use of MELD Scores and SII in Hepatic Visceral Crisis in Patients with Solid Tumours.
    Tay F; Buyukkor M; Duran AO
    J Coll Physicians Surg Pak; 2023 Aug; 33(8):879-883. PubMed ID: 37553926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.
    Fang N; Zhang HQ; He B; Xie M; Lu S; Wan YY; Wang NR
    Tumour Biol; 2014 Apr; 35(4):3261-8. PubMed ID: 24282088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of balloon-occluded transvenous obliteration of gastric varices and gastrorenal shunts on the hepatic synthetic function: a comparison between Child-Pugh and model for end-stage liver disease scores.
    Saad WE; Wagner CC; Al-Osaimi A; Bliebel W; Lippert A; Davies MG; Sabri SS; Turba UC; Matsumoto AH; Angle JF; Caldwell S
    Vasc Endovascular Surg; 2013 May; 47(4):281-7. PubMed ID: 23681780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
    Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
    Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18.
    Biselli M; Dall'Agata M; Gramenzi A; Gitto S; Liberati C; Brodosi L; Ravaioli M; Gambato M; Montalti R; Pinna AD; Burra P; Gerunda GE; Cillo U; Andreone P; Bernardi M
    Liver Int; 2015 Jan; 35(1):184-91. PubMed ID: 24650058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of Model for End-Stage Liver Disease-Na in predicting morbidity and mortality following elective colon cancer surgery irrespective of underlying liver disease.
    Causey MW; Nelson D; Johnson EK; Maykel J; Davis B; Rivadeneira DE; Champagne B; Steele SR
    Am J Surg; 2014 Apr; 207(4):520-6. PubMed ID: 24239525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cirrhosis with ascites: Is the presence of hemorrhagic ascites an indicator of poor prognosis?
    Yıldız H; Akdoğan M; Suna N; Öztaş E; Kuzu UB; Bilge Z; Aydınlı O; Taşkıran İ
    Turk J Gastroenterol; 2016 Jul; 27(4):349-53. PubMed ID: 27124284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MELD score in advanced liver disease: association with clinical portal hypertension and mortality.
    Saab S; Landaverde C; Ibrahim AB; Durazo F; Han S; Yersiz H; Farmer DG; Ghobrial RM; Goldstein LI; Tong MJ; Busuttil RW
    Exp Clin Transplant; 2006 Jun; 4(1):395-9. PubMed ID: 16827633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites.
    Yoo HY; Edwin D; Thuluvath PJ
    Am J Gastroenterol; 2003 Jun; 98(6):1395-9. PubMed ID: 12818287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of model for end-stage liver disease score with discriminant function and child-Turcotte-Pugh scores for predicting short-term mortality in Korean patients with alcoholic hepatitis].
    Jeong JY; Sohn JH; Son BK; Paik CH; Kim SH; Han DS; Jeon YC; Lee MH; Lee DH; Kee CS
    Korean J Gastroenterol; 2007 Feb; 49(2):93-9. PubMed ID: 17322788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
    Cui S; Ba M; Tang Y; Liu J; Wu Y; Wang B; Zhang X; Tang H; Zhong S
    Oncol Rep; 2012 Oct; 28(4):1325-31. PubMed ID: 22797826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
    Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment.
    Alessandria C; Gaia S; Marzano A; Venon WD; Fadda M; Rizzetto M
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):607-12. PubMed ID: 15167164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based incorporation of serum sodium concentration into MELD.
    Biggins SW; Kim WR; Terrault NA; Saab S; Balan V; Schiano T; Benson J; Therneau T; Kremers W; Wiesner R; Kamath P; Klintmalm G
    Gastroenterology; 2006 May; 130(6):1652-60. PubMed ID: 16697729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.